Combination drug therapy for triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of three drugs (cyclophosphamide, axatilimab, and retifanlimab) for people with metastatic triple negative breast cancer. The goal is to see if adding a low dose of chemotherapy can make the immunotherapy work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple negative breast cancer that has spread or cannot be removed with surgery, and standard treatments no longer work.
- You have not had chemotherapy or radiation in the last week.
- You are at least 18 years old.
- You have a tumor that can be measured on a scan.
- You are generally healthy enough to be up and about (ECOG score 0-2).
- Your liver, kidney, and blood cell counts are within certain ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for metastatic triple-negative breast cancer, using radiation to stimulate the immune system, an immunotherapy drug (pembrolizumab), and a medication that targets immune-suppressing cells. The goal is to boost the body's response to immunotherapy, especially in people who have already received immunotherapy but saw limited benefit.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a combination of an immunotherapy drug (camrelizumab), a chemotherapy drug (nab-paclitaxel), and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if adding the allergy medicine helps the treatment work better.
This trial tests a combination of a PD-L1 antibody (a type of immunotherapy) with a low-dose, continuous chemotherapy regimen called VEX for advanced triple-negative breast cancer that has spread to other parts of the body. It may be an option if you have had only one prior chemotherapy for metastatic disease and have already been treated with certain common chemo drugs.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.